MitraClip in Primary and Secondary Mitral Regurgitation
For primary MR, surgical mitral valve repair remains the gold standard, with MitraClip reserved for symptomatic patients at prohibitive surgical risk; for secondary MR, MitraClip is indicated for symptomatic patients with severe MR (LVEF 20-50%, LVESD <70mm) who remain symptomatic despite optimal medical therapy. 1
Primary Mitral Regurgitation
First-Line Treatment
- Surgical mitral valve repair is the preferred treatment for severe primary MR with unanimous guideline agreement 2
- Surgery is indicated for symptomatic chronic primary MR or asymptomatic patients with LVEF ≤60% and/or LVESD ≥40mm 2
- Surgical repair should be prioritized over valve replacement when a durable repair can be achieved 2
MitraClip Indications in Primary MR
MitraClip is indicated only for highly selected primary MR patients who cannot undergo surgery: 1
- Symptomatic patients (NYHA class III-IV) with severe (3+ or 4+) primary degenerative MR 1
- Prohibitive surgical risk due to severe comorbidities 1
- Favorable anatomy for the repair procedure 3
- Reasonable life expectancy despite optimal guideline-directed medical therapy 3
Critical Limitations in Primary MR
- MitraClip is contraindicated when leaflets are restricted in both systole and diastole (Carpentier IIIA motion, such as rheumatic or radiation heart disease) because it would cause mitral stenosis 1
- Residual MR rates are significantly higher with MitraClip compared to surgery (43.1% vs 5.4% at discharge; 66.7% vs 33.3% at 1 year) 4
- Reintervention rates are higher with MitraClip (87.5% freedom from reintervention at 1 year vs 100% for surgery) 4
Secondary Mitral Regurgitation
Foundation of Treatment
Guideline-directed medical therapy (GDMT) is the cornerstone of secondary MR management and must be optimized before considering any intervention: 5
- ACE inhibitors or ARBs 3
- Beta blockers 3
- Aldosterone antagonists 3
- Cardiac resynchronization therapy (CRT) when appropriate 1, 3
- Coronary revascularization if ischemic etiology 1, 3
MitraClip Indications in Secondary MR
MitraClip is indicated for patients meeting ALL of the following criteria: 1, 6
- Severe secondary MR (3+ or 4+) that persists after optimization of GDMT 1, 6
- LVEF between 20% and 50% 1, 6
- LV end-systolic diameter <70mm 1, 6
- Symptomatic despite maximally tolerated GDMT as verified by a heart failure specialist 6
- Evaluation and approval by a multidisciplinary heart team experienced in heart failure and mitral valve disease 6
Evidence Base: COAPT vs MITRA-FR
The divergent results of these landmark trials highlight critical patient selection factors: 6
COAPT (positive results):
- Demonstrated 47% reduction in heart failure hospitalizations 6
- Showed 38% reduction in all-cause mortality at 24 months 6
- Patients had more severe MR (higher effective regurgitant orifice areas) 6
- Patients had less LV remodeling (lower LV end-diastolic volumes) 6
- Required verified maximally tolerated GDMT by heart failure specialist 6
- Conducted in comprehensive heart valve centers with prior MitraClip experience 6
MITRA-FR (neutral results):
- No difference in death or heart failure hospitalizations at 12 months 6
- Patients had less severe MR relative to LV size 6
- More variable heart failure medication use 6
- Higher rates of residual MR 6
Surgical Considerations in Secondary MR
- Surgery for secondary MR has NOT been shown to improve mortality despite improving functional outcomes and quality of life in selected patients 6
- Surgery is reasonable when coronary artery bypass grafting is indicated 2
- Surgery may be considered for symptomatic patients despite optimal GDMT, but evidence is limited 2
Diagnostic Requirements
Severity Assessment
Severe MR is defined by integration of multiple echocardiographic parameters: 2
- Vena contracta ≥7mm 2
- Effective regurgitant orifice area (EROA) ≥0.4 cm² for primary MR 2
- EROA ≥0.2 cm² for secondary MR 2
- Regurgitant volume ≥60 mL/beat for primary MR 2
- Regurgitant volume ≥30 mL/beat for secondary MR 2
- Regurgitant fraction ≥50% 2
Imaging Modalities
- Transthoracic echocardiography is fundamental for diagnosis 2
- Transesophageal echocardiography is required for pre-procedural planning, intraoperative imaging, and post-intervention assessment 2
- Exercise testing or stress echocardiography is important in asymptomatic patients to unmask symptoms 2
Common Pitfalls
Patient Selection Errors:
- Attempting MitraClip in primary MR patients who are suitable surgical candidates—this compromises outcomes and may complicate future surgery 4, 7
- Proceeding with MitraClip in secondary MR before optimizing GDMT—this was a key difference between COAPT and MITRA-FR 6
- Using MitraClip in patients with excessive LV dilatation (LVESD >70mm) where outcomes are poor 1
Technical Considerations: